Molecular Imaging and PET-Guided Dose Escalation Revolutionize Salvage Radiotherapy: Insights from EMPIRE-1 and EMPIRE-2
The EMPIRE trials demonstrate that integrating molecular imaging and PET-guided dose escalation significantly improves event-free survival in patients requiring salvage radiotherapy for prostate cancer recurrence.

